{
  "id": 8454746,
  "title": "Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?",
  "url": "https://urgent.news/2026/09/18/should-you-buy-jazz-pharmaceuticals-stock-after-its-actio-acquisition-8454746",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T10:42:00.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/buy-jazz-pharmaceuticals-stock-actio-104200902.html"
  },
  "original_language": "en",
  "account": "Jazz Pharmaceuticals recently paid $820 million to acquire Actio Biosciences, a small biotech company working on a potential new treatment for a rare form of childhood epilepsy. The deal is expected to be completed by the end of September. In addition to the upfront payment, Actio shareholders may receive another $500 million in milestone payments if their experimental drug ABS-1230 proves effective. However, ABS-1230 has not yet been approved and is still in the early stages of clinical development.\n\nWhat's unique about this deal is that Jazz is acquiring a company whose pipeline directly aligns with one of its existing major businesses. Jazz already has a strong presence in the rare epilepsy market through its FDA-approved epilepsy medication Epidiolex, which generated $292 million in sales in Q2. ABS-1230 could potentially expand that franchise into an area with virtually no currently available treatments. KCNT1-related epilepsy is an extremely rare genetic disorder affecting around 2,500 patients in the U.S. Existing antiseizure drugs show limited efficacy for this condition, and there are currently no FDA-approved treatments. Early clinical trial results for ABS-1230 show promising reductions in seizures in children, and the drug has received several FDA designations that could expedite its development.\n\nWhile the $820 million upfront cost is substantial, particularly given the small patient population, Jazz is not dependent on ABS-1230 alone for future growth. In Q2, Jazz reported a 16% year-over-year revenue increase to $1.2 billion, with sales of its sleep disorder treatment Xywav up 13% and its epilepsy drug Epidiolex up 16%. The company raised its 2026 revenue guidance to $4.6 billion to $4.75 billion. Additionally, Jazz generated $824 million in operating cash flow in the first half of 2026, providing financial flexibility for future acquisitions and existing clinical programs.\n\nDespite the promise of ABS-1230, a small proof-of-concept study is far from definitive clinical evidence. There's always a risk that clinical setbacks could make this acquisition a costly mistake. And this isn't the first major acquisition Jazz has made in recent years - in 2025, they paid $944 million for Chimerix, a company with promising oncology assets. This strategy of using acquisitions to build growth beyond their core epilepsy and sleep franchises appears to be working, as Jazz is steadily increasing its revenue and cash flow.\n\nHowever, the Actio acquisition alone isn't enough to make Jazz Pharmaceuticals an obvious buy, as there's significant clinical work remaining for ABS-1230. The company's stock trades at about 9.5 times forward earnings, which is reasonable for a profitable biotech with growing products and a strong pipeline. While Jazz doesn't make the Motley Fool's top 10 stock list, they do appear to be an interesting and potentially attractive long-term growth opportunity for investors comfortable with the inherent risks of investing in biotech stocks.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?",
        "url": "https://urgent.news/2026/09/18/should-you-buy-jazz-pharmaceuticals-stock-after-its-actio-acquisition",
        "published": "2026-09-18T10:22:00.000Z"
      },
      {
        "outlet": "Nasdaq Markets",
        "title": "Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?",
        "url": "https://urgent.news/2026/09/18/should-you-buy-jazz-pharmaceuticals-stock-after-its-actio-acquisition-8230919",
        "published": "2026-09-18T10:42:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}